Fintel reports that on October 1, 2024, Wedbush initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with a Outperform recommendation.
Analyst Price Forecast Suggests 81.71% Upside
As of September 25, 2024, the average one-year price target for Perspective Therapeutics is $22.95/share. The forecasts range from a low of $17.17 to a high of $28.35. The average price target represents an increase of 81.71% from its latest reported closing price of $12.63 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Perspective Therapeutics is 11MM, an increase of 641.60%. The projected annual non-GAAP EPS is -0.13.
What is the Fund Sentiment?
There are 145 funds or institutions reporting positions in Perspective Therapeutics. This is an increase of 23 owner(s) or 18.85% in the last quarter. Average portfolio weight of all funds dedicated to CATX is 0.17%, an increase of 40.33%. Total shares owned by institutions decreased in the last three months by 84.06% to 39,860K shares. 
The put/call ratio of CATX is 2.79, indicating a bearish outlook.
What are Other Shareholders Doing?
Commodore Capital holds 4,657K shares representing 6.91% ownership of the company.
Janus Henderson Group holds 4,444K shares representing 6.59% ownership of the company.
Avidity Partners Management holds 3,038K shares representing 4.51% ownership of the company.
Deerfield Management Company, L.p. holds 2,818K shares representing 4.18% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,690K shares representing 2.51% ownership of the company.
Perspective Therapeutics Background Information
(This description is provided by the company.)
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
